CliffBio
biologic

Kedbumin

Albumin (Human)

Loss of exclusivityJune 2023projected — 12-year biologic exclusivity estimate
CompanyKedrion Biopharma, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameKedbumin
Active ingredientAlbumin (Human)
Strength12.5G/50ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2011
Marketing statusRx

More from Kedrion Biopharma, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kedbumin patent cliff — loss of exclusivity June 2023 | CliffBio